Daniel S. Lorrain, Chief Scientific Officer: Contineum Therapeutics CTNM Planned sale · Filed 10/01

Trade details

Type: Planned sale notice
Stock: Contineum Therapeutics CTNM
Person: Daniel S. LorrainChief Scientific Officer
Planned sale date: 26/10/01
Filed: 26/10/01

More to sell after $325.4K in 3 months

Contineum Therapeutics trades, last 26 weeks

What else happened in Contineum Therapeutics around then

Filed or reported within 30 days of the trade day · 09/01~10/31

Daniel S. Lorrain's recent trades

Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$154.6K
9,520 sh
$154.6K
Filed 09/01
Traded 09/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$147.5K
9,520 sh
$147.5K
Filed 08/03
Traded 08/03
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$156K
9,520 sh
$156K
Filed 07/01
Traded 07/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$432.4K
28,826 sh
$432.4K
Filed 06/30
Traded 06/30
Daniel S. LorrainChief Scientific Officer
Sell10b5-1 planContineum Therapeutics
Sell10b5-1 plan
Contineum Therapeutics
CTNM
$54.9K
4,170 sh
$54.9K
Filed 06/01
Traded 06/01